Cargando…
Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: a multicenter retrospective cohort study
BACKGROUND: Immune checkpoint inhibitors (ICI)-based combination strategies have improved the survival outcomes in advanced non-small cell lung cancers; however, data regarding their efficacy remains limited for uncommon histological types, including large-cell carcinoma (LCC) and large-cell neuroen...
Autores principales: | Song, Lianxi, Zhou, Fei, Xu, Tian, Zeng, Liang, Xia, Qing, Wang, Zhan, Deng, Li, Li, Yizhi, Qin, Haoyue, Yan, Huan, Huang, Zhe, Mi, Jinye, Xu, Qinqin, Yang, Nong, Zhou, Caicun, Zhang, Yongchang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186661/ https://www.ncbi.nlm.nih.gov/pubmed/37189075 http://dx.doi.org/10.1186/s12885-023-10952-w |
Ejemplares similares
-
Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer
por: Song, Lianxi, et al.
Publicado: (2022) -
Intracranial activity of first-line immune checkpoint inhibitors combined with chemotherapy in advanced non-small cell lung cancer
por: Huang, Zhe, et al.
Publicado: (2023) -
Complete and durable response of pulmonary large‐cell neuroendocrine carcinoma to pembrolizumab
por: Kadota, Naoki, et al.
Publicado: (2021) -
Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study
por: Zhang, Yongchang, et al.
Publicado: (2022) -
Pulmonary large cell carcinoma with neuroendocrine morphology shows genetic similarity to large cell neuroendocrine carcinoma
por: Liang, Zuoyu, et al.
Publicado: (2022)